Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination therapy consisting of four classes of cardiovascular drugs: - **Nitrates** (e.g., glyceryl trinitrate, isosorbide mononitrate): Vasodilators that relax and widen blood vessels, improving blood flow to the heart and relieving angina symptoms. - **Clopidogrel**: An antiplatelet agent (P2Y12 inhibitor) that prevents platelets from sticking together, reducing the risk of clot formation. - **Aspirin**: An antiplatelet agent that inhibits platelet aggregation by blocking cyclooxygenase, further reducing clot risk. - **Statins** (e.g., atorvastatin, simvastatin): Lipid-lowering agents that inhibit HMG-CoA reductase to reduce cholesterol synthesis in the liver and lower LDL cholesterol. This combination targets multiple mechanisms involved in coronary artery disease and acute coronary syndromes. It is commonly used for secondary prevention after myocardial infarction or in patients with stable angina or high cardiovascular risk. The regimen reduces recurrent ischemic events by addressing thrombosis (aspirin/clopidogrel), hyperlipidemia (statins), and myocardial oxygen supply/demand imbalance (nitrates)[1][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nitrates + clopidogrel + aspirin + statins.